ADMA Biologics Inc (NASDAQ:ADMA) has earned an average rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $10.50.
Several equities analysts recently issued reports on the company. Raymond James set a $10.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Friday. Oppenheimer set a $13.00 target price on ADMA Biologics and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Maxim Group reissued a “buy” rating and issued a $12.00 target price on shares of ADMA Biologics in a research note on Wednesday, September 5th. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Finally, Chardan Capital initiated coverage on ADMA Biologics in a research note on Monday, July 30th. They issued a “buy” rating and a $10.00 target price on the stock.
ADMA Biologics stock opened at $5.23 on Friday. The stock has a market capitalization of $287.83 million, a P/E ratio of -2.74 and a beta of 2.35. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $6.96. The company has a current ratio of 10.65, a quick ratio of 8.88 and a debt-to-equity ratio of 0.79.
ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $4.66 million during the quarter, compared to the consensus estimate of $5.35 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. As a group, equities analysts predict that ADMA Biologics will post -1.31 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new stake in shares of ADMA Biologics during the first quarter worth about $182,000. BlackRock Inc. raised its position in shares of ADMA Biologics by 59.5% during the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 15,115 shares during the period. AMP Capital Investors Ltd acquired a new stake in shares of ADMA Biologics during the second quarter worth about $109,000. 683 Capital Management LLC raised its position in shares of ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after purchasing an additional 80,000 shares during the period. Finally, Ardsley Advisory Partners acquired a new stake in shares of ADMA Biologics during the second quarter worth about $361,000. 55.08% of the stock is currently owned by institutional investors.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Article: Does the discount rate affect the economy?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.